Investor Relations
Invest in the Future of Diagnostics.
Invest in Transforming Healthcare Through Innovation, One product at a Time.
​​At DRUiD, we are reimagining diagnostics to address the interconnected health of people, animals, and the environment—guided by our One Health mission.
Our patented Hydrogel Biosensor Platform drives high-impact innovation, delivering scalable solutions for some of the world’s most pressing health challenges.
With a strategic focus on community-based diagnostics, our current pipeline is laser-focused on revolutionizing the diagnosis and management of urinary tract infections (UTIs), a critical area in the fight against antimicrobial resistance (AMR).
​
Our first intervention is only the beginning. With a high-growth pipeline targeting female health, AMR, and other emerging diagnostic needs, DRUiD is poised to create a transformational impact across global healthcare markets.
Why Invest in DRUiD?
High-Growth Market Opportunity
With over 200 million UTI cases annually and rising demand for solutions to combat AMR, our laser focus on UTI diagnostics positions us to disrupt a $10B+ global market.
Scalable Pipeline for Long-Term Returns
Starting with our Vita platform, our strategic pipeline includes innovative solutions for female health and beyond, unlocking multiple revenue streams through product sales, and co-development partnerships.
One Health, One Mission
Our One Health approach addresses interconnected challenges across human, animal, and environmental health, aligning with global healthcare priorities for sustainable, scalable impact.
​Proven Leadership and Cutting-Edge Technology
Led by industry experts in biosensor manufacture. DRUiD combines patented biosensor technology with a clear, actionable vision—delivering rapid market entry, high scalability, and exceptional ROI potential.
In-Licencing & Partnership
Global Access Through Perpetual In-Licensing
DRUiD operates under a perpetual licence from iDE8 for the development, manufacture, and sale of cutting-edge technologies for One Health applications worldwide.
This strategic in-licensing approach minimises R&D risks by leveraging proven innovations, significantly reducing development costs and accelerating time to market.
​
By integrating advanced technologies into our portfolio, we expand opportunities in high-growth areas like FemTech and UTI diagnostics, strengthening our position in emerging markets.
These partnerships also provide access to expertise and networks, creating a competitive edge while driving scalable, impactful healthcare solutions globally
Seed Round
OUR ASK
We are seeking £4 million to reach key milestones leading to our regulatory submission.
This includes £1.5 million for operational expenses to enhance our team and R&D efforts, £1.5 million for capital expenditures to advance product development, and £1 million for comprehensive clinical trials to ensure the highest standards of safety and efficacy. This funding will position us ideally for market entry and scalable growth.
​
We invite interested investors to reach out for more detailed information on how your investment can drive innovation in medical diagnostics and create impactful health solutions. Join us in shaping the future of healthcare.
Seed Round In Numbers
£1.5M
CapEx
£1.5M
OpEx
£1M
Clinical trials
Strategic Support
Active Shareholders
